China National Biotech Group (CNBG), the vaccine and bioscience unit of China National Pharmaceutical Group (Sinopharm), is China’s largest and the world’s fifth largest human vaccine R&D and manufacturing enterprise, with an annual output of over 700 million vaccine doses.
Sinopharm CNBG is the first in the world to develop a COVID-19 inactivated vaccine, as well as the first to launch international phase III clinical trials for inactivated COVID-19 vaccines. To date, two inactivated COVID-19 vaccines developed and produced by Sinopharm are undergoing phase III clinical trials in multiple countries, including the UAE, Bahrain and Peru.
The company has built large-scale production facilities for inactivated COVID-19 vaccines in Beijing and Wuhan, with a combined capacity of 300 million vaccine doses per year.
